Catheter-based Denervation System for HFpEF

About Corveus Medical

Corveus Medical is an early-stage, pre-revenue medical device company focused on the significant unmet need in congestive heart failure (CHF). The company is developing a catheter-based system designed to ablate a specific nerve branch (likely the right greater splanchnic nerve) via a transvenous approach, aiming to halt disease progression in heart failure with preserved ejection fraction (HFpEF) patients. Founded in 2018 and operating from the Texas Medical Center, Corveus is led by a small core team and is in the pre-clinical or early clinical development stage. Its approach is supported by emerging scientific literature on the role of the sympathetic nervous system in HFpEF.

Therapeutic Areas